EnteroMedics Inc. has retired its Senior Amortizing Convertible Notes, converted all $18.75 million in notes to shares of common stock, as part of a strategy to regain compliance with the Nasdaq requirement that it have a minimum of $2.5 million of stockholders’ equity. Read More »
Dr. Dan Iosifescu, a well-known clinician-specialist specializing in mood disorders, has joined NYU Langone Medical Center's psychiatry faculty. Read More »
Sanofi's Soliqua 100/33 product to treat adults with Type 2 diabetes is now available via prescription in U.S. pharmacies. Read More »
MiMedx Group Inc. has filed lawsuits against two former sales employees for alleged breaches of contractual and common law obligations. Read More »
CVS Health Corp. President and CEO Larry Merlo spoke to investors this week at the 35th Annual J.P. Morgan Healthcare Conference. Read More »
The pharmaceutical research company TPD LLC (Trends in Pharma Development) recently announced its new line of PanX medicines for use in treating anxiety. The products will be available nationwide as prescription compounded drugs. Read More »
Factor One Source Pharmacy, a specialty pharmacy that serves individuals with complex or hard-to-manage medications, will acquire Fast Access Specialty Therapeutics, a quickly growing pharmacy that has made a name for itself through industry-leading customer satisfaction, patient engagement and strong financial performance. Read More »
Bayer AG and Versant Ventures recently announced a partnership to launch BlueRock Therapeutics. The joint venture will utilize breakthrough treatments in stem cell technology to cure a range of diseases. Read More »
Bayer recently announced the selection of Robert LaCaze as executive vice president in charge of the company’s new Oncology Strategic Business Unit at the Pharmaceuticals Division. Read More »
AcelRX Pharmaceuticals recently submitted a new drug application to the U.S. Food and Drug Administration for ARX-04. Read More »
CVS Health recently launched Transform Diabetes Care, a program dedicated to helping clients improve member health outcomes. Read More »
Marrk Merritt, president and CEO of the Pharmaceutical Care Management Association, writes, "The truth is PBMs reduce costs for payers and consumers by 30 percent or more and are part of the solution. It’s time for drug manufacturers to take responsibility for their own business mistakes instead of blaming others." Read More »
Endo International, PLC, a subsidiary of Par Pharmaceutical, recently released mycophenolate mofetil hydrochloride (HCI) in the U.S. following Food and Drug Administration approval of its Abbreviated New Drug Application. Read More »
The Centers for Disease Control and Prevention has awarded $184 million in funding to various groups in an effort to protect Americans from Zika virus infection. Read More »
Medinol, a global Interventional Cardiology device company, recently announced positive twelve-month clinical results from its BIONICS study. The study was conducted to analyze and evaluate EluNIR, the company’s coronary stent system and the first ever elastomer-coated drug eluting stent (eDES). Read More »
The American Journal of Health-System Pharmacy has applauded the 21st Century Cures Act was signed into law by President Barack Obama on Dec. 13. Read More »
Teva Pharmaceuticals Industries Ltd. (Teva) recently announced a settlement with the United States government related to allegations of violating the Foreign Corrupt Practices Act (FCPA) in Ukraine, Mexico and Russia. Read More »
Direct Relief recently announced that it airlifted 82 tons of medical aid to Haiti for the treatment of cholera and other diseases that have become rampant since Hurricane Matthew in October. Read More »
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, recently partnered with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). Read More »
Genentech, a member of the Roche Group, recently announced that the primary endpoint for the Phase III HAVEN 1 study has been met. The study evaluates emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. Read More »
Alerts Sign-up
